TEG002

TEG002 is an investigational autologous cell therapy in which a patient's own αβ-T cells are engineered to express a defined γδ-T cell receptor (specifically the Vγ9Vδ2 TCR). This modification enables the modified T cells to recognize and kill tumor cells independently of MHC-I expression. Upon administration, these engineered cells secrete interferon-gamma (IFN-γ) and exert direct cytotoxic effects on tumor targets. The approach is being developed as a novel immunotherapy for cancers such as relapsed/refractory multiple myeloma and neuroblastoma. Preclinical studies have shown that TEG002 can efficiently kill neuroblastoma organoids independent of their MHC-I status and may offer superior efficacy compared to unmodified αβ-T or endogenous γδ-T cells[1][3][5]. Clinical trials are ongoing in multiple myeloma[2][4].

Other names

TEG-002TEG002TEG 002